Intensive Diabetes Treatment Reduces Complications, Ups Survival

Risk for CV events and microvascular (with exception of peripheral neuropathy) complications down.
Risk for CV events and microvascular (with exception of peripheral neuropathy) complications down.

(HealthDay News) -- Early, intensified intervention in type 2 diabetes patients with microalbuminuria increases life span, with patients more likely free from severe complications, according to a study published online in Diabetologia.

The new study included 160 Danish individuals who had type 2 diabetes and microalbuminuria. The participants were randomly assigned to conventional therapy or an intensified, multifactorial treatment that included behavioral and pharmacological intervention.

Continue Reading Below

Thirty-eight intensive-therapy patients and 55 conventional-therapy patients died during follow-up of 21.2 years (hazard ratio, 0.55). The average survival was a median of 7.9 years longer for patients in the intensive-therapy group versus the conventional-therapy group. The median time to first cardiovascular event was 8.1 years longer in the intensive-therapy group, and the risk for all microvascular complications was decreased in the intensive-therapy group with the exception of peripheral neuropathy.

"Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological and behavioral actions increased life span. And, that extra life length is free from severe and feared complications," senior author Oluf Pedersen, MD, a specialist in internal medicine and endocrinology for the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen in Denmark, told HealthDay.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Source

1. Gæde, P, Oellgaard, J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. doi:10.1007/s00125-016-4065-6.

Loading links....

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.